A-Fib, Blood Thinners, Risk of Stroke and Dementia

Share Button

Parkinson’s disease, alcohol abuse, and the absence of a blood-thinning treatment seemed to be the “strongest predictors for dementia (dem).”

I have chronic A-Fib. I worry about my heart and brain health. I chose not to take conventional blood thinners such as warfarin, Eliquis or Pradaxa  because of the risk of long-term side effects. My read of the article/study linked an excerpted below is that it is thinner blood that reduces my risk of stroke and dementia not taking conventional FDA approved anticoagulants that reduce my risk of stroke and dementia.

Image result for image of dementia patient

Let me direct. There are risks on both sides of this issue.  I run risks by going the natural blood thinning route alone and there are risks by going the convention blood thinning route as well.

I take omega 3 fatty acids, nattokinase, curcumin and digestive enzymes for a variety of health reasons. All of these supplements have been shown to thin a person’s blood.

I take and recommend Life Extension Super Omega 3 fatty acids, and Life Extension Super Bio-Curcumin. Both have been evaluated and approved by Consumerlab.com and both formulas have been shown to be more absorbable than conventional formulas.

Please scroll down the page, post a question or comment and I will reply to you ASAP.

Thank you,

David Emerson

  • Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:

Blood thinners slash dementia risk in A-fib patients

“New research published in the European Heart Journal suggests that blood-thinning drugs such as warfarin may protect not only against stroke, but also against dementia in people who have atrial fibrillation…

But the precise role of anticoagulant, or blood-thinning, drugs on dementia risk is not yet known and has not been sufficiently investigated, explain the authors.

One theory suggests that, since anticoagulants prevent stroke by protecting against large blood clots, they should also prevent dementia by protecting against the small blood clots and microinfarctions that characterize it…

The researchers also wanted to see whether or not the type of anticoagulant made any difference — such as whether newer blood thinners had a different effect on dementia risk when compared with old ones

To this end, Friberg and Rosenqvist reviewed the history of 444,106 Swedish patients with A-fib between 2006 and 2014. At the beginning of the study, 54 percent of these patients were not taking oral blood thinners. During the study period, 26,210 of all patients developed dem.

A-fib patients who were on a blood-thinning treatment at the beginning of the study were 29 percent less likely to develop dem than those who were not.

Also, an “on-treatment analysis” revealed that patients who continued to take the anticoagulants had a 48 percent lower risk of dementia.

Parkinson’s disease, alcohol abuse, and the absence of a blood-thinning treatment seemed to be the “strongest predictors for dem.”

The findings provide strong evidence that oral blood thinners may prevent dem in patients with A-fib. “In order to prove this assumption,” they explain, “randomized placebo controlled trials would be needed, but […] such studies cannot be done because of ethical reasons.”

“It is not possible to give placebo to [A-fib] patients and then wait for dem or stroke to occur,” write Friberg and Rosenqvist.

Finally, the study found no difference between warfarin — which represents an older generation of anticoagulants — and newer ones.”

Leave a Comment:

1 comment
Add Your Reply